STOCK TITAN

Pacira Biosciences (PCRX) Stock News

PCRX Nasdaq

Welcome to our dedicated page for Pacira Biosciences news (Ticker: PCRX), a resource for investors and traders seeking the latest updates and insights on Pacira Biosciences stock.

Pacira BioSciences reports developments across a commercial portfolio of non-opioid pain management and regenerative health products. Its recurring updates center on EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain, ZILRETTA® extended-release intra-articular corticosteroid injection for osteoarthritis, and the iovera° cold-therapy device for targeted nerve pain control.

Company news also covers earnings and product revenue trends, real-world evidence on opioid use and healthcare costs, pipeline development involving ZILRETTA, iovera° and PCRX-201, share repurchases, equity inducement awards, and stockholder governance matters tied to board composition and proxy materials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.67%
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.51%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.43%
Tags
none
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.97%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.48%
Tags
conferences earnings
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.13%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.9%
Tags
conferences
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.17%
Tags
-
Rhea-AI Summary

Pacira BioSciences, Inc. (NASDAQ:PCRX) will report its first quarter financial results on May 3, 2023, before U.S. market opening. A conference call is scheduled for 8:30 a.m. ET the same day. Participants may pre-register for Q&A via telephone to receive dial-in details. The event will also be available as a live webcast. Pacira focuses on non-opioid pain management solutions and offers three commercial products: EXPAREL®, ZILRETTA®, and ioveraº®. These innovative interventions aim to reduce dependence on opioids and address various pain-related conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
conferences earnings
Rhea-AI Summary

Pacira BioSciences, Inc. has partnered with the Invited Celebrity Classic, a PGA TOUR Champions event, to promote non-opioid pain management using its device, iovera°. The device applies targeted cold therapy to alleviate chronic and acute pain without medications. Paul Goydos, a professional golfer, joins as a brand ambassador to raise awareness of iovera°.

The partnership includes on-site activations and education at various golf tournaments throughout the year, with the inaugural event occurring from April 21-23, 2023, at the Las Colinas Country Club. This initiative aims to highlight the benefits of non-opioid options and reduce reliance on opioid medications, which carry substantial addiction risks. Pacira currently focuses on redefining pain management through innovation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.44%
Tags
partnership

FAQ

What is the current stock price of Pacira Biosciences (PCRX)?

The current stock price of Pacira Biosciences (PCRX) is $22.84 as of May 12, 2026.

What is the market cap of Pacira Biosciences (PCRX)?

The market cap of Pacira Biosciences (PCRX) is approximately 894.8M.